FOLR1 ( Folate receptor alpha )

We then quantify its ability to image many different cancer types in murine tumor models and combine it in different ratios with pafolacianine to determine the ratio that yields the highest total tumor fluorescence and tumor-to-background ratio in seven tumor models. Because the combination of the two fluorescent conjugates invariably images tumors better than either conjugate alone, and since the two-dye combination displays no obvious toxicities, we propose that a cocktail of FAP9-S0456 plus pafolacianine warrants evaluation as a candidate for intraoperative imaging of all human tumors.

FOLR1 is overexpressed in a large percentage of low-grade serous ovarian cancers. Mirvetuximab soravtansine may represent a novel treatment option for low-grade serous ovarian cancer patients progressing after standard treatment modalities. Clinical trials with mirvetuximab soravtansine in FOLR1-positive low-grade serous ovarian cancers are warranted.

GEM-loaded CaP NPs showed high cytotoxicity in FRα-overexpressing cancer cell lines (MCF-7, MDA-MB-231, HeLa), while FA conjugation significantly reduced toxicity in hMSCs without compromising anticancer activity. These findings demonstrate the potential of FA-conjugated and GEM-loaded CaP NPs as a nanoplatform for targeted cancer therapy with reduced toxicity in healthy cells.

Negative studies such as this are essential for evidence-based clinical decision-making, preventing unnecessary resource allocation and potential patient exposure to ineffective interventions. These findings inform the broader fluorescence-guided surgery field and support continued investigation of alternative targeting strategies for HNSCC.

Furthermore, co-culturing immature dendritic cells with dying cancer cells targeted by EGFR and TF NIR-PIT agents mediated enhanced dendritic cell maturation, as indicated by increased expression of CD80, CD86, CD40, and HLADR. Taken together, our results suggested that all five investigated NIR-PIT agents have great potential to be applicable for ovarian cancer treatment.

P1/2, N=764, Recruiting, Genmab | N=569 --> 764

Importantly, this modular conjugation platform allows for facile replacement of ligands, enabling the rational design of receptor-directed AAV vectors for targeted and cell-specific gene therapy. These findings provide mechanistic insights into capsid-receptor interactions and establish a flexible strategy for precision engineering of AAV-based delivery systems.

Regarding the conjugation type, only trastuzumab deruxtecan, labetuzumab govitecan, sacituzumab govitecan, BYON3521, and SYD1875 used homogeneous conjugation. An interesting observation was that for some ADCs, TAA expression was higher in normal tissue than in the tumor. In summary, our analysis highlights that only a limited number of ADCs incorporate payloads with favorable physicochemical properties and that several ADCs currently under development target TAAs with higher expression in normal tissues than in the corresponding tumors.

Furthermore, we propose an innovative four-part mRNA vaccine approach to balance therapeutic effectiveness with clinical practicalities. Both vaccine formulations showed intense immune stimulation in silico, indicating their potential as promising candidates for immunotherapy against TNBC, which will require further experimental exploration.

Mirvetuximab soravtansine-gynx, an FRα-targeting ADC, has been approved by the FDA and EMA for the treatment of FRα-positive, platinum-resistant ovarian cancer... These findings highlight the critical importance of standardized, validated assays for FRα detection to ensure accurate patient selection for targeted therapies. The study emphasizes the need for further optimization of alternative antibodies before clinical implementation.

Complete resection and advanced stage were suggested as prognostic factors in UCS. FRα and Trop-2 are increasingly recognized as therapeutic targets and their elevated expression levels in the epithelial component of UCS are promising, although not associated with prognosis in this cohort.

These findings highlight the IMS's potential for efficiently discovering high-affinity and high-specificity biomolecular probes. The selected aptamer was successfully applied in a detection assay to quantify FRα, underscoring the system's promise for early ovarian cancer diagnosis.